pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

3,393 catalysts · 4,728 grant · 3,603 8k filing · 2,712 approval · 2,670 device 510k · 2,000 device recall · 1,887 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: recall×type: approval×from 2025-06-13×clear all
type
  • grant4,728
  • 8k filing3,603
  • approval2,712
  • device 510k2,670
  • device recall2,000
  • device pma1,887
device adverse event
1,000
  • recall681
  • earnings585
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Jun 9, 2025

    6
    ›Jun 13, 2025approval444d agoCLOZAPINE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: IVAX SUB TEVA PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 13, 2025approval444d agoCLOZAPINE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: IVAX SUB TEVA PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 13, 2025approval444d agoLEVOCETIRIZINE DIHYDROCHLORIDE — FDA approvalLEVOCETIRIZINE DIHYDROCHLORIDE

    Sponsor: MICRO LABS LTD INDIA. Form: TABLET. Route: ORAL

    full page →LEVOCETIRIZINE DIHYDROCHLORIDE →fda approvals ↗
    ›Jun 13, 2025approval444d agoLEVOCETIRIZINE DIHYDROCHLORIDE — FDA approvalLEVOCETIRIZINE DIHYDROCHLORIDE

    Sponsor: MICRO LABS LTD INDIA. Form: TABLET. Route: ORAL

    full page →LEVOCETIRIZINE DIHYDROCHLORIDE →fda approvals ↗
    ›Jun 13, 2025approval444d agoLEVOCETIRIZINE DIHYDROCHLORIDE — FDA approvalLEVOCETIRIZINE DIHYDROCHLORIDE

    Sponsor: MICRO LABS LTD INDIA. Form: TABLET. Route: ORAL

    full page →LEVOCETIRIZINE DIHYDROCHLORIDE →fda approvals ↗
    ›Jun 13, 2025approval444d agoSTEQEYMA (USTEKINUMAB-STBA) — FDA approvalSTEQEYMA

    Sponsor: CELLTRION, INC.. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →STEQEYMA →fda approvals ↗

    Week of Jun 16, 2025

    25
    ›Jun 16, 2025approval441d agoARYNTA (LISDEXAMFETAMINE DIMESYLATE) — FDA approvalLISDEXAMFETAMINE DIMESYLATE

    Sponsor: AZURITY. Form: SOLUTION. Route: ORAL

    full page →LISDEXAMFETAMINE DIMESYLATE →fda approvals ↗
    ›Jun 17, 2025approval

    Week of Jun 23, 2025

    18
    ›Jun 23, 2025approval434d agoAMITRIPTYLINE HYDROCHLORIDE — FDA approvalAlgoTherapeutix SAS

    Sponsor: UNIQUE PHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 23, 2025approval

    Week of Jun 30, 2025

    1
    ›Jul 1, 2025approval426d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ← prev
    page 1 of 68
    next →
    440d ago
    XARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 17, 2025approval440d agoXARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jun 17, 2025approval440d agoMEFENAMIC ACID — FDA approvalMEFENAMIC ACID

    Sponsor: MICRO LABS. Form: CAPSULE. Route: ORAL

    full page →MEFENAMIC ACID →fda approvals ↗
    ›Jun 17, 2025approval440d agoTREMFYA (GUSELKUMAB) — FDA approvalguselkumab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →guselkumab →fda approvals ↗
    ›Jun 18, 2025approval439d agoDUPIXENT (DUPILUMAB) — FDA approvaldupilumab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

    full page →dupilumab →fda approvals ↗
    ›Jun 18, 2025approval439d agoZEJULA (NIRAPARIB TOSYLATE) — FDA approvalniraparib

    Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL

    full page →niraparib →fda approvals ↗
    ›Jun 18, 2025approval439d agoZEJULA (NIRAPARIB TOSYLATE) — FDA approvalniraparib

    Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL

    full page →niraparib →fda approvals ↗
    ›Jun 18, 2025approval439d agoISOTRETINOIN — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: ACTAVIS LABS FL. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jun 18, 2025approval439d agoENBREL (ETANERCEPT) — FDA approvalAMGEN INC

    Sponsor: IMMUNEX. Form: SYRINGE

    full page →fda approvals ↗
    ›Jun 18, 2025approval439d agoAXTLE (PEMETREXED DIPOTASSIUM) — FDA approvalAXTLE

    Sponsor: AVYXA HOLDINGS. Form: POWDER. Route: INTRAVENOUS

    full page →AXTLE →fda approvals ↗
    ›Jun 18, 2025recall439d agoZydus Pharmaceuticals (USA) Inc recall (Cls II)LB PHARMACEUTICALS INC

    Icosapent Ethyl Capsules 1 gram, 120 Capsules per Bottle, Rx Only, Manufactured by Doppel Farmaceutici s.r.l., Piacenza, Italy, Distributed by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1592-7. — Reason: Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage of capsule contents. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoAvKARE recall (Cls II)AvKare LLC

    Chlorthalidone Tablets, USP, 25 mg, 50 Tablets (5x10) Unit Dose cards per carton, Rx only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-167-15 — Reason: Failed Dissolution Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoSAINI TRADE INC recall (Cls I)

    ELECTRO BUZZ, Dietary Supplement, 10 capsules per box, Distributed By: Health Fixer, Tempe, AZ 85288, UPC B0DK68LF6J. — Reason: Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared chloropretadalafil, propoxyphenylsildenafil, and sildenafil. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoAscend Laboratories, LLC recall (Cls II)Ascend Laboratories Ltd

    Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 200 mL (when mixed), Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascent Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-544-68 — Reason: Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoAlembic Pharmaceuticals Limited recall (Cls II)Alembic Pharmaceuticals Inc

    Celecoxib Capsules, 200 mg, 500-count bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division), Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-142-71 — Reason: Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoAmneal Pharmaceuticals, LLC recall (Cls I)Amneal Pharmaceuticals, Inc.

    Sulfamethoxazole and Trimethoprim Tablets, USP, 400 mg/80 mg, Rx Only, a) 100 Tablets per Bottle, NDC: 65162-271-10, b) 500 Tablets per Bottle, NDC: 65162-271-50, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad, 382213, INDIA, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. — Reason: Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoSAINI TRADE INC recall (Cls I)

    ULTRA ARMOR, My Armor My Power, Dietary Supplement, 10 capsules per box, Distributed by Health Fixer, Tempe, AZ 85288, UPC B0CYJ7Y5H9. — Reason: Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoAvKARE recall (Cls II)AvKare LLC

    Celecoxib Capsules, 200 mg, 50 Capsules (5x10) Unit Dose per carton, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478. NDC 50268-169-15 — Reason: Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoAscend Laboratories, LLC recall (Cls II)Ascend Laboratories Ltd

    Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed), Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascent Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-544-88 — Reason: Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoSAINI TRADE INC recall (Cls I)

    Male Ultra Pro, Unleash Your Force 2, 10 capsules per box, Distributed by: Health Fixer Tempe AZ 85288, UPC B0CZN7C6YH. — Reason: Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoSAINI TRADE INC recall (Cls I)

    MALEXTRA, Recharge with Extra, Dietary Supplement, 10 capsules per box, Distributed by: Health Fixer, Tempe, AZ 85288, UPC B0CWKZ6ZP3. — Reason: Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoSAINI TRADE INC recall (Cls I)

    Male Ultra, Unleash Your Force, Dietary Supplement,10 capsules per box, Distributed By; Health Fixer, Tempe, AZ 85288, UPC B0CMQ4FTHG. — Reason: Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoMacleods Pharmaceuticals Ltd recall (Cls III)Telix Pharmaceuticals Ltd

    Levothyroxine Sodium Tablets, USP 112 mcg (0.112mg), 1000 tablets, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540. Manufactured by: Macleods Pharmaceuticals Ltd. Sarigam, Valsad, Gujarat, India, NDC 33342-398-44. — Reason: Presence of a foreign substance: black hair found embedded in tablet. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 18, 2025recall439d agoGlenmark Pharmaceuticals Inc., USA recall (Cls III)LB PHARMACEUTICALS INC

    Ezetimibe and Simvastatin Tablets, 10mg/40mg, 90-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Madya Pradesh, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-323-90 — Reason: Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study. — Status: Ongoing

    full page →fda recalls ↗
    434d ago
    HADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    ›Jun 24, 2025approval433d agoTRAZODONE HYDROCHLORIDE — FDA approvalTRAZODONE HYDROCHLORIDE

    Sponsor: APOTEX INC. Form: TABLET. Route: ORAL

    full page →TRAZODONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 24, 2025approval433d agoTRAZODONE HYDROCHLORIDE — FDA approvalTRAZODONE HYDROCHLORIDE

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →TRAZODONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 24, 2025approval433d agoMETHADOSE (METHADONE HYDROCHLORIDE) — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 24, 2025approval433d agoRALDESY (TRAZODONE HYDROCHLORIDE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: KAMAT. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Jun 25, 2025approval432d agoMETHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 25, 2025recall432d agoUmary-USA.com recall (Cls I)OCULAR THERAPEUTIX, INC

    UNAVY ACIDO HIALURONICO, Conenido: 30 capletas de 850mg, distribuido por: EREN NATURAL S.A. DE C.V, Zappan, Jal. C.P, UPC 7 503046 054295 — Reason: Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone, Diclofenac and Omeprazole. — Status: Completed

    full page →fda recalls ↗
    ›Jun 25, 2025recall432d agoAurobindo Pharma USA Inc recall (Cls II)Aurobindo Pharma USA Inc

    Acetaminophen Tablets, 325 mg, 100-count bottles, Distributed by: Amazon.com Services LLC, 410 Terry Avenue N., Seattle, WA 98109, NDC 72288-405-10 — Reason: cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets). — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 25, 2025recall432d agoEugia US LLC recall (Cls II)Eugia US LLC

    Gentamicin Injection, USP, (PEDIATRIC), 20 mg per 2 mL (10 mg per mL*), 2 mL Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ, 08520 Vial- NDC 55150-401-01, Carton NDC 55150-401-25 — Reason: Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis. — Status: Ongoing

    full page →fda recalls ↗
    ›Jun 25, 2025recall432d agoUmary-USA.com recall (Cls I)OCULAR THERAPEUTIX, INC

    UMOVY ACIDO HIALURONICO, Conenido: 30 capletas de 850mg, distribuido por: EREN NATURAL S.A. DE C.V, Zappan, Jal. C.P, UPC 7503046054134 — Reason: Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone and Diclofenac. — Status: Completed

    full page →fda recalls ↗
    ›Jun 26, 2025approval431d agoPUR-WASH (PURIFIED WATER) — FDA approval

    Sponsor: NIAGARA PHARMS. Form: SOLUTION. Route: OPHTHALMIC

    full page →fda approvals ↗
    ›Jun 26, 2025approval431d agoCAPRELSA (VANDETANIB) — FDA approvalvandetanib

    Sponsor: GENZYME CORP. Form: TABLET. Route: ORAL

    full page →vandetanib →fda approvals ↗
    ›Jun 27, 2025approval430d agoSTELARA (USTEKINUMAB) — FDA approvalJOHNSON & JOHNSON

    Sponsor: CENTOCOR ORTHO BIOTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jun 27, 2025approval430d agoSTELARA (USTEKINUMAB) — FDA approvalustekinumab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →ustekinumab →fda approvals ↗
    ›Jun 27, 2025approval430d agoGAMIFANT (EMAPALUMAB-LZSG) — FDA approvalSobi Inc

    Sponsor: NOVIMMUNE S.A.. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jun 27, 2025approval430d agoPYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalPYZCHIVA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →PYZCHIVA →fda approvals ↗
    ›Jun 27, 2025approval430d agoULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approvalAlexion Pharmaceuticals Inc

    Sponsor: ALEXION PHARM. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    $BMY66.58-0.55%
    $AMRX17.54-2.61%
    $AMGN432.42-1.05%
    $TLX
    $REGN794.19-1.67%
    $LBRX47.73-0.33%
    $OCUL10.36-4.25%
    $LBRX47.73-0.33%
    $OCUL10.36-4.25%
    $JNJ268.04+0.85%